NEW YORK (GenomeWeb) – Nanosphere reported after the close of the market on Wednesday that its revenues rose 42 percent year over year, driven by a sharp uptick in consumables sales.

However, Nanosphere fell short of analysts' consensus estimates and lowered its guidance for the year. Investors drove shares of the firm down 29 percent to $1.01 in Thursday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.